---
title: "Streptococcus"
date: 2025-09-10T20:55:03+02:00
draft: false
description: "Complete explanation of the pathophysiology of S. aureus, epidermidis, and saprophyticus"
subjects: ["Microbiology"]
systems: ["Pathology", "Microbiology"]
tags: ["Microbiology"]
---


# Streptococci — high-yield deep dive



## Quick overview

* Gram-positive cocci, usually appearing in **chains** (or pairs for some species).
* **Catalase negative** (key to separate from Staphylococci).
* Facultative anaerobes.
* Classified by **hemolysis on blood agar** (alpha, beta, gamma) and by **Lancefield grouping** (group-specific cell wall carbohydrates, e.g., Group A = *S. pyogenes*, Group B = *S. agalactiae*).
* Important clinical species: **S. pyogenes (GAS)**, **S. agalactiae (GBS)**, **S. pneumoniae**, **viridans group streptococci**, **Enterococcus** (formerly group D).



# Classification / quick map

* **Beta-hemolytic (complete hemolysis)**

  * *Group A*: Streptococcus pyogenes — bacitracin sensitive, PYR +
  * *Group B*: Streptococcus agalactiae — CAMP test +, hippurate +
  * Groups C/G: S. dysgalactiae, S. anginosus group (can cause pharyngitis, abscesses)
* **Alpha-hemolytic (partial/green)**

  * *S. pneumoniae* — optochin sensitive, bile soluble, lancet-shaped diplococci
  * *Viridans streptococci* (S. mutans, S. sanguinis, S. mitis) — optochin resistant, normal oral flora
* **Gamma / non-hemolytic or variable**

  * *Enterococcus faecalis / faecium* — bile esculin +, growth in 6.5% NaCl, PYR +



# Lab ID shortcuts (memorize)

* **Catalase negative** → streptococci.
* **Bacitracin (A) disk sensitive** = *S. pyogenes* (GAS).
* **PYR test positive** = GAS and Enterococcus.
* **CAMP test positive** = GBS (*S. agalactiae*) — arrowhead augmentation of hemolysis next to S. aureus streak.
* **Optochin sensitive & bile soluble** = *S. pneumoniae*.
* **Bile esculin + and growth in 6.5% NaCl** = Enterococcus.
* **Hippurate hydrolysis +** = *S. agalactiae*.



# 1) Streptococcus pyogenes (Group A) — the big one

### Micro/virulence

* Beta-hemolytic; bacitracin sensitive; PYR +.
* Key virulence factors:

  * **M protein**: antiphagocytic; many emm types; major determinant for rheumatic fever molecular mimicry.
  * **Hyaluronic acid capsule**: anti-phagocytic (mimics host).
  * **Streptolysin O & S**: hemolysins (S is oxygen stable; O is oxygen labile and antigenic → ASO antibodies).
  * **Streptokinase** (fibrinolysin) — helps spread.
  * **DNases**, **hyaluronidase**, **C5a peptidase** (disrupts neutrophil recruitment).
  * **Pyrogenic exotoxins (SpeA, SpeB, SpeC, etc.)** — superantigens → scarlet fever rash, streptococcal toxic shock.

### Diseases / clinical syndromes

* **Suppurative (direct infection):** pharyngitis (strep throat), impetigo, cellulitis, erysipelas, necrotizing fasciitis (Type II), bacteremia, puerperal sepsis.
* **Toxin-mediated:** scarlet fever (pharyngitis + sandpaper rash + Pastia lines) and streptococcal toxic shock syndrome (STSS).
* **Post-infectious immune sequelae:**

  * **Acute rheumatic fever (ARF)** — follows untreated/undertreated **pharyngitis** (not skin infections).
  * **Poststreptococcal glomerulonephritis (PSGN)** — nephritic syndrome; follows **pharyngitis or skin infection (impetigo)** (immune complex deposition).

### Pathogenesis notes

* Adhesion (lipoteichoic acid, M protein), tissue invasion (enzymes), immune evasion (M protein, capsule) → local damage + systemic toxin effects (superantigen cytokine storm in STSS).
* **ARF**: molecular mimicry between M protein and cardiac myosin / other components → autoimmune attack on heart (Aschoff bodies) — **Jones criteria** for diagnosis (see below).
* **PSGN**: immune complex deposition in glomeruli → hypocomplementemia (low C3 often temporary).

### Diagnosis

* Clinical + **rapid antigen detection test (RADT)** for GAS (specific high, sensitivity moderate). Negative RADT with high suspicion → **throat culture** on blood agar (gold standard).
* Serology for recent infection: **ASO titers** (peak weeks after infection; useful for ARF) and **anti-DNase B** (useful after skin infections where ASO may be normal).

### Treatment

* **First-line:** Penicillin (oral phenoxymethylpenicillin or IM benzathine penicillin for prophylaxis). Amoxicillin also used.
* **Penicillin allergy:** macrolides (erythromycin/azithro), but macrolide resistance exists (know local rates).
* **Severe invasive disease (necrotizing fasciitis, STSS):** IV **penicillin** plus **clindamycin** (clindamycin inhibits protein synthesis → reduces toxin production; also works in stationary phase). Early surgical debridement for nec fasc. Consider IVIG in streptococcal toxic shock in refractory cases (neutralizes superantigens) — used as adjunct in severe disease.

### Exam pearls (GAS)

* Rheumatic fever follows **pharyngitis** but not skin infections. PSGN can follow either.
* **ASO** rises after GAS pharyngitis; **anti-DNase B** helpful after impetigo.
* **M protein** = major virulence factor + molecular mimicry → rheumatic heart disease.



# 2) Streptococcus agalactiae (Group B)

### Micro/virulence

* Beta-hemolytic (sometimes weak), **CAMP test +**, hippurate hydrolysis +. Colonizes female genital tract and rectum.

### Clinical importance

* **Neonatal disease**: early onset sepsis/pneumonia (first 24–48 hours, acquired intrapartum) and late onset meningitis (weeks after birth).
* In adults: UTIs, skin/soft tissue infections, bacteremia—esp. in diabetics, elderly.

### Prevention & treatment

* **Pregnancy screening** at \~35–37 weeks (rectovaginal swab). **Intrapartum antibiotic prophylaxis** (IV penicillin G or ampicillin) for colonized women or those with risk factors (e.g., prolonged rupture of membranes, intrapartum fever, previous infant with GBS disease).
* **Penicillin** is first-line. For severe penicillin allergy, use clindamycin **only if isolate susceptible**; otherwise, vancomycin (local policies apply).



# 3) Streptococcus pneumoniae

### Micro/virulence

* **Alpha-hemolytic**, **optochin sensitive**, **bile soluble**, lancet-shaped diplococci. Polysaccharide capsule is major virulence factor (antiphagocytic). Pneumolysin (pore forming), IgA protease.

### Clinical syndromes

* **Community-acquired pneumonia** (classically lobar consolidation), otitis media, sinusitis, **meningitis**, bacteremia. Risk increased in asplenic patients, sickle cell, elderly, alcoholics.

### Diagnosis

* Gram stain (gram + diplococci), culture, urine antigen test (for pneumococcal antigen) in adults with pneumonia, bile solubility test or optochin disk.

### Treatment & resistance

* Historically penicillin; **resistance** through altered penicillin-binding proteins (PBP) is common — empiric therapy for severe disease (e.g., meningitis) often includes **ceftriaxone/cefotaxime + vancomycin** until susceptibilities known.
* For non-severe pneumonia, choose therapy based on local resistance patterns. Vaccines: **conjugate vaccines (PCV13/15/20 etc.)** and **polysaccharide (PPSV23)** — memorize indications per adult/child schedule (important clinically/exam).



# 4) Viridans group streptococci

* Normal oral flora; **alpha-hemolytic**, optochin resistant.
* Important for **dental caries (S. mutans)** and **subacute bacterial endocarditis** (especially after dental procedures in patients with preexisting valve damage).
* Treatment: penicillin (often with gentamicin for synergy in endocarditis depending on the case).



# 5) Enterococcus (E. faecalis, E. faecium)

### Micro/clinical

* Gram-positive cocci, **bile esculin +**, grow in **6.5% NaCl**, **PYR +**. Normal GI flora. Causes UTIs, biliary sepsis, and **subacute endocarditis**.

### Resistance & treatment challenges

* Intrinsically less susceptible to many antibiotics (cephalosporins ineffective). Endocarditis often needs **ampicillin + gentamicin** (synergy).
* **Vancomycin-resistant Enterococcus (VRE)** — genes **vanA/vanB** → D-Ala→D-Lac change — serious nosocomial problem. Options: **linezolid, daptomycin, tigecycline**, newer agents exist (know institutionally available choices).



# Mechanisms of antibiotic resistance (concise)

* **S. pneumoniae**: altered PBPs → reduced penicillin susceptibility.
* **Macrolide resistance** (GAS & pneumococcus): **erm** (methylase → target modification; can cause inducible clindamycin resistance) or **mef** (efflux pump). Use **D-test** to detect inducible clindamycin resistance.
* **Enterococcus**: **vanA/vanB** change D-Ala-D-Ala to D-Ala-D-Lac → vancomycin resistance.



# Immunologic sequelae: ARF vs PSGN (high-yield exam points)

* **Rheumatic fever (ARF)**

  * Follows **GAS pharyngitis**, \~2–3 weeks after infection.
  * **Jones major criteria** — JONES: *J*oints (migratory arthritis), *O* (carditis), *N*odules subcutis (subcutaneous nodules), *E*rythema marginatum, *S*ydenham chorea.
  * Requires evidence of preceding GAS infection (positive throat culture, RADT, or elevated ASO/anti-DNase B). Chronic consequence = rheumatic heart disease (valvular scarring, MR → MS).
* **Poststreptococcal glomerulonephritis (PSGN)**

  * Immune complex deposition in glomeruli → nephritic syndrome: hematuria (cola urine), oliguria, hypertension, edema.
  * May follow **pharyngitis OR skin infection (impetigo)**. Complement C3 often low (transient).



# Clinical & lab troubleshooting pearls

* **Negative RADT** but high clinical suspicion for GAS pharyngitis → **do throat culture** (RADT sensitivity not perfect).
* **ASO** useful for evidence of recent GAS exposure in suspected ARF. **Anti-DNase B** may be more helpful after skin infections.
* Severe invasive GAS infections → **penicillin + clindamycin** (clinda suppresses toxin production). In necrotizing fasciitis, early **surgical debridement** is lifesaving.
* **CAMP test** = essential to identify GBS (neonatal implications).
* **Optochin** distinguishes *S. pneumoniae* (sensitive) from viridans (resistant).



# High-yield mnemonics & memory aids

* **JONES** for major criteria of rheumatic fever (see above).
* **PYR** test positive = **P**yrrolidonyl arylamidase → GAS and **P** (Enterococcus) — both PYR+.
* **CAMP** = **C**onfirms **A**galactiae **M**aking arrowhead (think “CAMP arrowhead”).



# Quick practice questions (with brief answers)

1. Q: A child has sore throat and fever. RADT negative. What next?
   A: If high clinical suspicion (Centor criteria etc.), perform a throat culture (RADT sensitivity imperfect). Treat based on culture / clinical context.

2. Q: A neonate presents with respiratory distress within 24 hours of birth; maternal rectovaginal swab was unknown. Organism suspected? Prevention?
   A: **GBS (S. agalactiae)** early-onset sepsis. Prevention: screen at 35–37 weeks and give **intrapartum IV penicillin** to colonized mothers.

3. Q: Patient with rapidly progressive soft-tissue infection, severe pain out of proportion, systemic toxicity. Gram stain shows gram + cocci in chains. Next steps?
   A: Suspect **necrotizing fasciitis** due to GAS → urgent surgical debridement + IV broad-spectrum antibiotics including high-dose penicillin and **clindamycin**; supportive ICU care.



# Two-day focused checklist (if you want a cram plan now)

* Day 1 AM: Read taxonomy + lab ID tests; memorize bacitracin/PYR/CAMP/optochin/bile esculin/6.5% NaCl rules.
* Day 1 PM: GAS deep dive — virulence, diseases, complications (ARF, PSGN), labs (ASO/anti-DNase B), treatment pearls (penicillin, clindamycin for toxins). Do 10 rapid cases.
* Day 2 AM: GBS, S. pneumoniae, viridans, Enterococcus — clinical syndromes, prevention (GBS screening; pneumococcal vaccines), resistance.
* Day 2 PM: Practice 15–20 mixed clinical vignettes with an emphasis on lab tests and management choices.
